Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Sells $130,812.00 in Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $59.46, for a total value of $130,812.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Daniel N. Swisher, Jr. also recently made the following trade(s):

• On Monday, November 11th, Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock. The shares were sold at an average price of $59.88, for a total value of $131,736.00.

Corcept Therapeutics Trading Down 1.6 %

Shares of CORT stock opened at $55.40 on Friday. The company has a market cap of $5.80 billion, a PE ratio of 43.97 and a beta of 0.51. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. The stock’s 50 day simple moving average is $53.06 and its two-hundred day simple moving average is $41.22. Corcept Therapeutics Incorporated has a 1 year low of $20.84 and a 1 year high of $62.22.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.14. The company had revenue of $182.55 million for the quarter, compared to analyst estimates of $171.97 million. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. Corcept Therapeutics’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.28 EPS. Research analysts predict that Corcept Therapeutics Incorporated will post 1.35 earnings per share for the current year.

Analyst Ratings Changes

CORT has been the topic of several recent analyst reports. Sandler O’Neill reiterated a “buy” rating on shares of Corcept Therapeutics in a research report on Friday, October 18th. StockNews.com cut Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, November 25th. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price objective on shares of Corcept Therapeutics in a report on Thursday, October 31st. Piper Sandler raised their target price on shares of Corcept Therapeutics from $38.00 to $67.00 and gave the company an “overweight” rating in a report on Wednesday, September 18th. Finally, Truist Financial upped their price target on shares of Corcept Therapeutics from $65.00 to $76.00 and gave the company a “buy” rating in a research note on Monday, September 30th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Corcept Therapeutics presently has an average rating of “Buy” and an average target price of $65.25.

Institutional Investors Weigh In On Corcept Therapeutics

Institutional investors have recently made changes to their positions in the company. M&G PLC purchased a new stake in Corcept Therapeutics in the 3rd quarter worth about $11,173,000. Empowered Funds LLC bought a new position in shares of Corcept Therapeutics during the third quarter valued at approximately $1,784,000. Victory Capital Management Inc. raised its holdings in shares of Corcept Therapeutics by 49.2% in the third quarter. Victory Capital Management Inc. now owns 41,823 shares of the biotechnology company’s stock worth $1,936,000 after buying an additional 13,787 shares during the period. Milestone Asset Management LLC lifted its stake in shares of Corcept Therapeutics by 47.4% during the 2nd quarter. Milestone Asset Management LLC now owns 51,599 shares of the biotechnology company’s stock worth $1,676,000 after acquiring an additional 16,593 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Corcept Therapeutics by 20.0% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 859,563 shares of the biotechnology company’s stock valued at $39,781,000 after acquiring an additional 143,507 shares during the period. Institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.